GW Pharma's cannabis-derived combo med helps brain cancer patients
“Median survival for the THC:CBD group was greater than 550 days compared with 369 days in the placebo group,” the biopharma said in a statement …
“Median survival for the THC:CBD group was greater than 550 days compared with 369 days in the placebo group,” the biopharma said in a statement …